Mid-Year Business Review 2024
Davipharm’s Mid-Year Business Review 2024 was held on August 22 in HCMC, with the entire Sales & MKT team and the related departments in attendance.
Some achievements from the first 7 months of 2024:
🌟 Growth (compared to the same period a year ago): Export +85%, Retail +35%
🌟 40 key brands with an average growth of 44%, making up 80% of retail, with some brands growing over 800%
🌟 Launched new products for treating premature ejaculation and erectile dysfunction; introduced the website themlauthemdamsau.com, where patients can self-assess, get advice via hotline, and order prescription drugs online
🌟 Added new features for loyalty program registration, sales tracking, and bonus estimation through Zalo OA for customers
🌟 Offered free NCDs screening and consultations at pharmacies in Hanoi and Da Nang
According to IQVIA’s report for Q1-2024, Davipharm ranks 21st position in the pharmaceutical market, and for domestic prescription drugs in the hospital channel, it is now the 5th largest company in terms of sales volume.
In September 2024, Davipharm plans to launch a medical website that will provide information on medications and diseases, as well as offer self-health screening tools.
We will continue to sponsor scientific seminars and hospital conferences reaching over 2,000 doctors; provide educational programs on diseases and products to 6,000 pharmacies nationwide; and participate in pharmaceutical exhibitions.
The retail channel aims to have Davipharm products in 20,000 pharmacies, with at least 10 products in each pharmacy.
Our goal is to complete NCDs free screening for a total of 10,000 patients, expanding to Daklak, Nha Trang, Can Tho, and HCMC.
Let’s keep striving toward our goals for the rest of the year!
